Free tool
FAERS Monitor: Camcevi Etm
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219745 or its brand name (Camcevi Etm, Leuprolide Mesylate). Reports on generic versions are filed under their own applications.
Reports
1,547
Serious
1,095
71% of reports
Hospitalization
513
Death reported
129
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective117
- fatigue93
- off label use90
- nausea79
- headache68
- malignant neoplasm progression62
- disease progression56
- vomiting49
- febrile neutropenia48
- product storage error45
- product use in unapproved indication41
- anaemia39
- dyspnoea39
- pain39
- acute kidney injury38
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 3 |
| 2011 | 6 |
| 2012 | 7 |
| 2013 | 27 |
| 2014 | 31 |
| 2015 | 31 |
| 2016 | 30 |
| 2017 | 62 |
| 2018 | 94 |
| 2019 | 151 |
| 2020 | 126 |
| 2021 | 140 |
| 2022 | 126 |
| 2023 | 135 |
| 2024 | 142 |
| 2025 | 229 |
| 2026 | 205 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,612 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 48 | 9.8 | 7.5 | 374 |
| malignant neoplasm progressionSignal | 62 | 8.2 | 6.5 | 389 |
| product storage errorSignal | 45 | 7.0 | 5.2 | 226 |
| disease progressionSignal | 56 | 6.4 | 5.0 | 253 |
| acute kidney injurySignal | 38 | 3.4 | 2.5 | 62 |
| anaemiaSignal | 39 | 2.8 | 2.0 | 43 |
| product use in unapproved indicationSignal | 41 | 2.2 | 1.7 | 28 |
| fatigue | 93 | 1.6 | 1.3 | 23 |
| headache | 68 | 1.5 | 1.2 | 10 |
| vomiting | 49 | 1.4 | 1.1 | 6 |
| off label use | 90 | 1.4 | 1.1 | 10 |
| nausea | 79 | 1.4 | 1.1 | 7 |
| drug ineffective | 117 | 1.2 | 1.0 | 4 |
| dyspnoea | 39 | 0.9 | 0.7 | 0 |
| pain | 39 | 0.9 | 0.6 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.